HydroWhirl S tank cleaning nozzle now ATEX certified

Published: 28-Feb-2012
Manufacturing Cleaning Pharmaceutical Active Nutrition Food

For use in atmospheres that are potentially explosive

The HydroWhirl S tank washing nozzle range from BETE has recently been expanded to include ATEX certified versions for use in atmospheres that are potentially explosive.

The HydroWhirl is designed to meet the exacting standards for effective cleaning-in-place (CIP) required in the pharmaceutical, chemical, food, dairy and beverage industries. As well as being certified for use in potentially explosive areas, the ATEX certified nozzles also meet the requirements for gas and dust approvals for all zones (0,1 and 2).

HydroWhirl nozzles are self-cleaning and self-lubricating, which eliminates the possibility of process contamination, while its compact design allows it to be fitted through small, restricted access flanges. They are ideal for medium tanks (up to 5 metres in diameter), used in the pharmaceutical and chemical, food and petrochemical industries, where superior cleaning combined with reduced cycle times, lower water, energy and chemical consumption are increasingly becoming important considerations.

See more

You may also like

Manufacturing

Faster tank cleaning with PTFE nozzle

Read more
HydroWhirl Poseidon removes scum rings and tougher residues

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  2. Miltenyi Biotec and CHA Biotech collaborate on BaEV lentiviral vector platform The pair will work to enhance CAR NK cell therapy manufacturing efficiency, combining Miltenyi Bioindustry's baboon envelope lentiviral vector platform with CHA Biotech's NK cell research expertise to improve gene delivery, scalability and cost of goods
  3. Simplifying continuous operations: lowering the barrier to faster development Continuous manufacturing has long promised faster development, improved process understanding and, in the absence of scale-up, smoother commercialization. For many pharmaceutical R&D teams, those benefits are well understood. What still holds them back, however, is not scepticism about the concept; it’s the perceived effort required to implement it
  4. Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Faster tank cleaning with PTFE nozzle

HydroWhirl Poseidon removes scum rings and tougher residues
Cleaning

Bete introduces high impact rotary tank cleaner

HydroWhirl Orbiter meets exacting cleaning standards
Manufacturing

Almac highlights SDS-PAGE approach for residual protein determination in new white paper

New white paper explores robust analytical method for residual protein detection in biocatalytic API manufacturing
Manufacturing

Reliable, high-performance pump for HPLC and UHPLC

Biotech Fluidics announce the ASI 540 – an affordable, standalone solvent delivery pump - design optimised for liquid chromatography applications
Regulatory

WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants

The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Regulatory

FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection

The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
Subscribe now